oral tirzepatide tablet GLP-1 for Weight Loss ORAL TIRZEPATIDE TABLETS

Kidney sections from all groups demonstrated normal renal architecture with intact glomeruli and tubules

10.1038/sj.ijo.0802491 234

According to the Phase 3b, double-blind, placebo-controlled STRIDE study, Ozempic (1 mg) resulted in a superior and clinically meaningful improvement of 13% in maximum walking distance and a mean treatment difference of 39.9 meters on a steep incline compared to placebo at week 52 in adults with T2DM and PAD. If approved, Ozempic will be the only GLP-1 receptor agonist indicated for the treatment of PAD in patients with T2DM

'I spoke to my gynecologist, and she agreed that I could take it and hopefully quickly lose weight,' she told Good Morning America